These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 29189042

  • 21. Detection of clinically signifi cant prostate cancer with PIRADS v2 scores, PSA density, and ADC values in regions with and without mpMRI visible lesions.
    Westphalen AC, Fazel F, Nguyen H, Cabarrus M, Hanley-Knutson K, Shinohara K, Carroll PR.
    Int Braz J Urol; 2019; 45(4):713-723. PubMed ID: 31136112
    [Abstract] [Full Text] [Related]

  • 22. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N, Wu YP, Chen DN, Ke ZB, Cai H, Wei Y, Zheng QS, Huang JB, Li XD, Xue XY.
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [Abstract] [Full Text] [Related]

  • 23. Prior Negative Biopsy, PSA Density, and Anatomic Location Impact Cancer Detection Rate of MRI-Targeted PI-RADS Index Lesions.
    Alzubaidi AN, Zheng A, Said M, Fan X, Maidaa M, Owens RG, Yudovich M, Pursnani S, Owens RS, Stringer T, Tracy CR, Raman JD.
    Curr Oncol; 2024 Aug 01; 31(8):4406-4413. PubMed ID: 39195312
    [Abstract] [Full Text] [Related]

  • 24. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
    Thaiss WM, Moser S, Hepp T, Kruck S, Rausch S, Scharpf M, Nikolaou K, Stenzl A, Bedke J, Kaufmann S.
    World J Urol; 2022 Oct 01; 40(10):2431-2438. PubMed ID: 35922717
    [Abstract] [Full Text] [Related]

  • 25. Prostate imaging-reporting and data system version 2 in combination with clinical parameters for prostate cancer detection: a single center experience.
    Wang L, Luo Y, Liu T, Deng M, Huang X.
    Int Urol Nephrol; 2023 Jul 01; 55(7):1659-1664. PubMed ID: 37171702
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer.
    Gündoğdu E, Emekli E, Kebapçı M.
    Radiol Med; 2020 Sep 01; 125(9):827-837. PubMed ID: 32266690
    [Abstract] [Full Text] [Related]

  • 27. Can combined multiparametric magnetic resonance imaging of the prostate and prostate-specific antigen density improve the detection of clinically significant prostate cancer: A prospective single-center cross-sectional study.
    Yadav K, Sureka B, Elhence P, Choudhary GR, Pandey H, Garg PK, Yadav T, Khera PS.
    J Cancer Res Ther; 2021 Sep 01; 17(2):372-378. PubMed ID: 34121679
    [Abstract] [Full Text] [Related]

  • 28. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
    Wei X, Xu J, Zhong S, Zou J, Cheng Z, Ding Z, Zhou X.
    Abdom Radiol (NY); 2022 Oct 01; 47(10):3574-3582. PubMed ID: 35788882
    [Abstract] [Full Text] [Related]

  • 29. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Kaufmann B, Saba K, Schmidli TS, Stutz S, Bissig L, Britschgi AJ, Schaeren E, Gu A, Langenegger N, Sulser T, Eberli D, Keller EX, Hermanns T, Poyet C.
    Prostate; 2022 Feb 01; 82(3):388-396. PubMed ID: 34914121
    [Abstract] [Full Text] [Related]

  • 30. Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer.
    Beksac AT, Ratnani P, Dovey Z, Parekh S, Falagario U, Roshandel R, Sobotka S, Kewlani D, Davis A, Weil R, Bashorun H, Jambor I, Lewis S, Haines K, Tewari AK.
    Cancer Rep (Hoboken); 2022 Mar 01; 5(3):e1492. PubMed ID: 34931468
    [Abstract] [Full Text] [Related]

  • 31. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer.
    Hansen NL, Barrett T, Kesch C, Pepdjonovic L, Bonekamp D, O'Sullivan R, Distler F, Warren A, Samel C, Hadaschik B, Grummet J, Kastner C.
    BJU Int; 2018 Jul 01; 122(1):40-49. PubMed ID: 29024425
    [Abstract] [Full Text] [Related]

  • 32. Prebiopsy multiparametric MRI and PI-RADS version 2.0 for differentiating histologically benign prostate disease from prostate cancer in biopsies: A retrospective single-center comparison.
    Tosun M, Uslu H.
    Clin Imaging; 2021 Oct 01; 78():98-103. PubMed ID: 33773450
    [Abstract] [Full Text] [Related]

  • 33. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    Tamada T, Kido A, Yamamoto A, Takeuchi M, Miyaji Y, Moriya T, Sone T.
    J Magn Reson Imaging; 2021 Jan 01; 53(1):283-291. PubMed ID: 32614123
    [Abstract] [Full Text] [Related]

  • 34. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A, Gawlitza J, Mucha S, Linder N, Franz T, Horn LC, Kahn T, Busse H.
    Eur J Radiol; 2019 Jul 01; 116():180-185. PubMed ID: 31153562
    [Abstract] [Full Text] [Related]

  • 35. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy.
    Yang S, Zhao W, Tan S, Zhang Y, Wei C, Chen T, Shen J.
    Transl Androl Urol; 2020 Jun 01; 9(3):1252-1261. PubMed ID: 32676408
    [Abstract] [Full Text] [Related]

  • 36. The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies.
    Görtz M, Radtke JP, Hatiboglu G, Schütz V, Tosev G, Güttlein M, Leichsenring J, Stenzinger A, Bonekamp D, Schlemmer HP, Hohenfellner M, Nyarangi-Dix JN.
    Eur Urol Focus; 2021 Mar 01; 7(2):325-331. PubMed ID: 31839564
    [Abstract] [Full Text] [Related]

  • 37. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN, Jia L, Subramanian N, Xi Y, Rofsky NM, Recchimuzzi DZ, de Leon AD, Arraj P, Pedrosa I.
    AJR Am J Roentgenol; 2021 Aug 01; 217(2):395-403. PubMed ID: 32876473
    [Abstract] [Full Text] [Related]

  • 38. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
    Pessoa RR, Viana PC, Mattedi RL, Guglielmetti GB, Cordeiro MD, Coelho RF, Nahas WC, Srougi M.
    BJU Int; 2017 Apr 01; 119(4):535-542. PubMed ID: 27500389
    [Abstract] [Full Text] [Related]

  • 39. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
    Falagario UG, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, Aronen HJ, Knaapila J, Perez IM, Gandaglia G, Fossati N, Martini A, Cucchiara V, Picker W, Haug E, Ratnani P, Haines K, Lewis S, Sujit N, Selvaggio O, Sanguedolce F, Macarini L, Cormio L, Nordström T, Tewari A, Briganti A, Boström PJ, Carrieri G.
    Eur Urol Oncol; 2021 Dec 01; 4(6):971-979. PubMed ID: 32972896
    [Abstract] [Full Text] [Related]

  • 40. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
    Faiella E, Santucci D, Greco F, Frauenfelder G, Giacobbe V, Muto G, Zobel BB, Grasso RF.
    Radiol Med; 2018 Feb 01; 123(2):143-152. PubMed ID: 29019021
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.